Bioatla, INC. (BCAB) — 10-Q Filings

10-Q Filings (6)

• BioAtla's Cash Dries Up Amidst Zero Revenue, Going Concern Doubts — Nov 13, 2025 Risk: high
  BioAtla, Inc. reported a significant decrease in cash and cash equivalents, falling from $49.046 million at December 31, 2024, to $8.320 million by September 30
• BioAtla Burns Cash on R&D, Reports $57.2M Net Loss in Q2 — Aug 7, 2025 Risk: high
  BioAtla, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its clinical-stage status. The company incurred a net loss o
• BioAtla, Inc. Q1 2025 10-Q Filing — May 6, 2025 Risk: medium
  BioAtla, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported its financial position and operational activities, including details on
• BioAtla Files Q3 2024 10-Q, Details R&D and Collaborations — Nov 7, 2024 Risk: medium
  BioAtla, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported research and development expenses for the nine months ended Septembe
• BioAtla Files Q2 2024 10-Q, Details Financials — Aug 8, 2024 Risk: medium
  BioAtla, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates. Key financial data points in
• BioAtla, Inc. Files 10-Q for Period Ending March 31, 2024 — May 14, 2024 Risk: low
  BioAtla, Inc. (BCAB) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. BioAtla, Inc. filed a 10-Q report for the period ending March 31, 2024. The f

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX